title: [Application of imatinib plus Hyper-CVAD chemotherapy regimen in patients with Ph chromosome positive acute lymphocytic leukemia].
abstract: OBJECTIVE
  To report the efficacy and safety of imatinib plus Hyper-CVAD chemotherapy regimen in the treatment of patients with ph chromosome positive acute lymphocytic leukemia (Ph(+)ALL).
  
  
  METHODS
  A sequential 2-year and 8-cycle treatment of imatinib plus Hyper-CVAD (A/B program) was administrated in 18 Ph(+)ALL patients treated at our hospital since January 2005 to January 2010. And another 18 Ph(+)ALL patients undergoing no allogeneic hematopoietic stem cell transplantation were selected as controls.
  
  
  RESULTS
  Among 18 patients on chemotherapy, their average age was 33.1 years, the total response rate 100% following induction chemotherapy and the median survival 28.8 (8.0 - 60.0) months. And the 1-, 2- and 3-year overall survival rates were 77.8%, 72.2% and 66.7% respectively. In control patients, the response rate following induction chemotherapy was 100% and the median survival 22.5 (4.0 - 58.0) months. And the 1-, 2- and 3-year overall survival rates were 66.7%, 55.6% and 50.0% respectively. A recent follow-up showed that 5 patients (27.8%) died from relapse in the chemotherapy group and 4 (22.2%) in the control group. The overall deaths were 6 (33.3%) in the chemotherapy group and 9 (50.0%) in the control group.
  
  
  CONCLUSIONS
  Imatinib plus Hyper-CVAD chemotherapy regimen is associated with significantly improved survival rates. Superior to allogeneic hematopoietic stem cell transplantation, it offers a prolonged median response time and survival time in Ph(+)ALL patients.
authors.affiliation: Department of Hematology, General Hospital, Beijing Military Area, Beijing 100700, China.
authors.forename: Zhi
authors.initials: Z
authors.lastname: Guo
authors.forename: Hui-ren
authors.initials: HR
authors.lastname: Chen
authors.forename: Xiao-dong
authors.initials: XD
authors.lastname: Liu
authors.forename: Kai
authors.initials: K
authors.lastname: Yang
authors.forename: Peng
authors.initials: P
authors.lastname: Chen
authors.forename: Bing
authors.initials: B
authors.lastname: Liu
authors.forename: Dan
authors.initials: D
authors.lastname: Liu
authors.forename: Bing-ran
authors.initials: BR
authors.lastname: Wang
authors.forename: Yu-shi
authors.initials: YS
authors.lastname: Yao
authors.forename: Xue-peng
authors.initials: XP
authors.lastname: He
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D011743:Pyrimidines / Q000008:administration & dosage; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate